Aurora Cannabis Reports Material Weakness in Internal Controls, Posts Significant Annual Loss, and Details Strategic Shifts

summarizeSummary

Aurora Cannabis disclosed a material weakness in its internal controls and reported a significant annual net loss, alongside strategic shifts including exiting the Canadian consumer market and a recent acquisition to bolster its global medical cannabis business.

check_boxKey Events

• Material Weakness in Internal Controls

  Management identified a material weakness in controls over biological asset and inventory valuation, leading to an adverse opinion from the auditor on the effectiveness of internal controls over financial reporting for the fiscal year ended March 31, 2026.

• Significant Annual Net Loss

  The company reported a net loss of $135.96 million for the fiscal year ended March 31, 2026, a substantial increase from a net income of $1.59 million in the prior year.

• Impairment Charges

  Aurora recognized approximately $34.1 million in impairment charges, including $13.2 million for Australian intangible assets and $18.7 million for goodwill related to the disposed Plant Propagation segment.

• Strategic Business Exits

  The company is exiting the lower-margin Canadian consumer cannabis market and completed the disposition of its 50.1% controlling interest in Bevo Agtech Inc. (Plant Propagation segment) on February 17, 2026.

auto_awesomeAnalysis

Aurora Cannabis filed its annual report, revealing a material weakness in internal controls over financial reporting related to biological asset and inventory valuation. The company's auditor, Ernst & Young LLP, issued an adverse opinion on the effectiveness of internal controls, though an unqualified opinion was given on the financial statements themselves. This indicates significant deficiencies in the processes for ensuring accurate financial reporting. Financially, the company reported a substantial net loss of $135.96 million for the fiscal year ended March 31, 2026, a sharp decline from a small net income in the prior year. This loss was partly driven by significant impairment charges totaling approximately $34.1 million, including intangible assets in Australia and goodwill related to the Plant Propagation segment. The company also detailed its strategic exit from the lower-margin Canadian consumer cannabis market to focus on global medical cannabis, and the disposition of its controlling interest in Bevo Agtech Inc. A new At-The-Market (ATM) program was established to raise up to U.S.$100 million, with $10.9 million already raised in FY26, and the acquisition of Safari Flower Company for $26.5 million was completed post-period end to expand EU GMP capacity.